Cagrilintide/semaglutide, marketed as CagriSema, is a combination of cagrilintide, a dual amylin and calcitonin receptor agonist, and semaglutide, a GLP-1 agonist. It is injected once weekly and is being tested in type 2 diabetes and obesity .

Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in...

Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual...

Jul 17, 2023 · CagriSema is a once-weekly injection of semaglutide and cagrilintide. CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes and weight management treatment.

Dec 26, 2024 · CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), that works by decreasing hunger and...

Dec 20, 2024 · CagriSema, a fixed dose of cagrilintide 2.4 mg and semaglutide 2.4 mg, achieved statistically significant weight loss after 68 weeks versus placebo.

Aug 26, 2023 · We found that treatment with co-administered semaglutide 2·4 mg and cagrilintide 2·4 mg (CagriSema) resulted in clinically relevant improvements in glycaemic control, including continuous glucose monitoring parameters, as well as significantly greater weight loss than either semaglutide or cagrilintide alone.

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and semaglutide 2.4 mg. The two molecules induce weight loss by reducing hunger, increasing feelings of fullness and thereby help people eat less and reduce their calorie intake.

Aug 26, 2023 · This trial assessed the efficacy and safety of co-administered semaglutide with cagrilintide (CagriSema) in participants with type 2 diabetes. Methods: This 32-week, multicentre, double-blind, phase 2 trial was conducted across 17 sites in the USA.

Aug 26, 2023 · In The Lancet, Juan P Frias and colleagues report positive results in a phase 2 trial evaluating the safety and efficacy of co-administered cagrilintide and semaglutide (CagriSema) for type 2 diabetes, 1 approximately 2 years after a phase 1b study showed early efficacy in the treatment of obesity. 2 The role of a gut–brain axis in energy ...